China Shineway Pharmaceutical Group Ltd. (2877) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd.

Zhongzhi Pharmaceutical Holdings Ltd.

China Shineway Pharmaceutical Group Ltd.

Shandong Xinhua Pharmaceutical Co., Ltd.

CK Life Sciences International (Holdings), Inc.

Sihuan Pharmaceutical Holdings Group Ltd.

HBM Holdings Ltd.

Wai Yuen Tong Medicine Holdings Ltd.

PuraPharm Corp. Ltd.

Hin Sang Group (International) Holding Co. Ltd.

China Health Group, Inc.

Why is China Shineway Pharmaceutical Group Ltd. ?

Poor long term growth as Operating profit has grown by an annual rate 8.54% of over the last 5 years

Negative results in Dec 24

ROCE(HY) Lowest at 11.61%
INTEREST COVERAGE RATIO(Q) Lowest at 10,647.85
INVENTORY TURNOVER RATIO(HY) Lowest at 1.11%

Below par performance in long term as well as near term

Along with generating -22.45% returns in the last 1 year, the stock has also underperformed Hang Seng Hong Kong in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is China Shineway Pharmaceutical Group Ltd. for you?

Low Risk, Low Return

Absolute

Risk Adjusted

Volatility

China Shineway Pharmaceutical Group Ltd.

-21.86%

-0.00

29.72%

Hang Seng Hong Kong

27.36%

1.03

25.88%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

5.19%

EBIT Growth (5y)

8.54%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.82

Sales to Capital Employed (avg)

0.54

Tax Ratio

26.68%

Dividend Payout Ratio

48.19%

Pledged Shares

Institutional Holding

ROCE (avg)

48.03%

ROE (avg)

10.55%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.90

EV to EBIT

0.67

EV to EBITDA

0.57

EV to Capital Employed

0.43

EV to Sales

0.15

PEG Ratio

Dividend Yield

0.02%

ROCE (Latest)

64.76%

ROE (Latest)

11.46%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend

Here's what is working for China Shineway Pharmaceutical Group Ltd.

Operating Cash Flow

Highest at HKD 2,300.83 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (HKD MM)

Cash and Eqv

Highest at HKD 6,906.92 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -82.28 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by 1.46% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for China Shineway Pharmaceutical Group Ltd.

Interest Coverage Ratio

Lowest at 10,647.85

in the last five periods

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Net Sales

Lowest at HKD 1,834.8 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (HKD MM)

Interest

Highest at HKD 3.55 MM

in the last five periods and Increased by 15.03% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (HKD MM)

Operating Profit

Lowest at HKD 378.52 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (HKD MM)

Operating Profit Margin

Lowest at 20.63 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at HKD 307.69 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (HKD MM)

Net Profit

Lowest at HKD 231.69 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (HKD MM)

Net Profit

Fallen at -55.14%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is negative

Net Profit (HKD MM)

EPS

Lowest at HKD 0.31

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (HKD)

Inventory Turnover Ratio

Lowest at 1.11%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio

Lowest at 2.92%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio